Not yet recruitingPhase 3NCT05813665
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
Studying Giant cell tumor of bone
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai JMT-Bio Inc.
- Principal Investigator
- Xiaohui Niu, B.M.Beijing Ji Shui Tan Hospital
- Intervention
- Narlumosbart(drug)
- Enrollment
- 146 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- Beijing Ji Shui Tan Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05813665 on ClinicalTrials.govOther trials for Giant cell tumor of bone
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07315828Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07227961PROMIS and Mobility Evaluation in Sarcoma PatientsUniversity of Calgary
- RECRUITINGPHASE1, PHASE2NCT06647901Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open StudyTang Xiaodong
- ACTIVE NOT RECRUITINGPHASE4NCT04586660Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the BoneAmgen
- RECRUITINGPHASE2NCT05595603Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional CurettageSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE3NCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of BoneSt. Louis University